60 Degrees Pharmaceuticals said its independent Data Safety Monitoring Board recommended continuing its Phase 2 B-Free chronic babesiosis study after reviewing safety data from the first six patients. The update is a positive procedural step, with no efficacy results or dosing changes disclosed in the provided excerpt. Overall, the news modestly improves the clinical risk profile versus an early pause.
60 Degrees Pharmaceuticals said its independent Data Safety Monitoring Board recommended continuing its Phase 2 B-Free chronic babesiosis study after reviewing safety data from the first six patients. The update is a positive procedural step, with no efficacy results or dosing changes disclosed in the provided excerpt. Overall, the news modestly improves the clinical risk profile versus an early pause.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.18
Ticker Sentiment
